Clinical Outcomes of Trimethoprim-Sulfamethoxazole with or Without Adjunctive Caspofungin in Patients with Moderate-to-Severe HIV-Associated Pneumocystis jirovecii Pneumonia: A Retrospective Cohort Study
Year: 2026
Type: article
Study design: Observational Study
Abstract: Purpose: To evaluate clinical outcomes of trimethoprim-sulfamethoxazole (TMP-SMX) with or without adjunctive caspofungin in patients with moderate-to-severe human immunodeficiency virus (HIV)-associated Pneumocystis jirovecii pneumonia (PJP), and explore factors associated with poor outcomes. Patients and Methods: Patients with HIV-associated PJP admitted to Beijing Youan Hospital from July 2020 to June 2026 were retrospectively included. Moderate-to-severe PJP was defined as arterial partial pressure of oxygen < 70 mmHg or alveolar-arterial oxygen gradient ≥ 35 mmHg on room air. Patients were grouped by regimen: TMP-SMX monotherapy or TMP-SMX plus caspofungin. The primary outcome was a composite of poor outcomes, including in-hospital death or discharge against medical advice due to poor prognosis. Between-group comparisons, a clinically specified multivariable logistic regression model, and a stabilized inverse probability of treatment weighting (IPTW) sensitivity analysis were performed. Results: Among 673 screened patients, 155 with moderate-to-severe HIV-associated PJP were analyzed after excluding mild cases and those with incomplete data; 78 received TMP-SMX monotherapy and 77 received TMP-SMX plus caspofungin. The combination group had longer hospital stays (P = 0.003) and higher procalcitonin levels (P = 0.044). Poor outcomes did not differ significantly between groups (P = 0.129). In the primary multivariable model adjusted for PaO 2 on room air and C-reactive protein (CRP), adjunctive caspofungin was not significantly associated with poor outcome (adjusted odds ratio [aOR] = 1.603, 95% confidence interval [CI]: 0.654– 3.925, P = 0.302). Lower PaO 2 (aOR = 0.958, 95% CI: 0.921– 0.996, P = 0.032) and higher CRP (aOR = 1.009, 95% CI: 1.000– 1.019, P = 0.047) were associated with poor outcome. The IPTW sensitivity analysis likewise showed no statistically significant association between adjunctive caspofungin and poor outcome (weighted OR = 1.939, 95% CI: 0.790– 4.763, P = 0.148). Conclusion: In this retrospective cohort, no statistically significant association was detected between TMP-SMX plus adjunctive caspofungin and poor outcomes in patients with moderate-to-severe HIV-associated PJP. Lower PaO 2 and higher CRP were associated with poor outcome in an exploratory adjusted analysis. Larger prospective multicenter studies are needed to clarify the role of adjunctive caspofungin. Keywords: human immunodeficiency virus, Pneumocystis jirovecii pneumonia, trimethoprim-sulfamethoxazole, caspofungin, poor outcome
Source: Infection and Drug Resistance
DOI: 10.2147/idr.s638117
Authors: Yu Wang, Caopei Zheng, Yuqing Sun, Yulin Zhang
Institutions: Capital Medical University, Beijing YouAn Hospital
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,836
Award: G6496786783
OpenAlex ID: W7225420184
